Ultane breathed in (inhalation) Liquid Liquid
PDF Leaflet Revision Date: 21 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Induction and maintenance of general anaesthesia in adults and paediatrics.
Dosage (summary)
Induction: titrate to effect; Maintenance: 0.5-3% concentration.
Onset of Action / Duration
Onset: <2 mins, Duration: variable based on concentration.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; use with caution in lactation.
Key Drug Interactions
- Beta-sympathomimetics
- Calcium antagonists
- Non-selective MAO-inhibitors
Contraindications
- Hypersensitivity to halogenated agents
- Malignant hyperthermia
- Neuromuscular disease
Common side effects
- Nausea
- Vomiting
- Hypotension
- Bradycardia
Counselling Points
- Monitor for respiratory depression
- Avoid activities requiring alertness post-anaesthesia
- Report any signs of hypersensitivity
Serious warnings
- Respiratory depression
- Malignant hyperthermia risk
- Hepatic dysfunction
Important Disclaimer
The Ultane breathed in (inhalation) Liquid Liquid professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
